| 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 晶泰控股(02228) | 21.30 亿元 | +5750.15 万元 | | 阿里巴巴-W(09988) | 20.54 亿元 | +1.98 亿元 | | 美团-W(03690) | 18.55 亿元 | -3.84 亿元 | | 腾讯控股(00700) | 18.12 亿元 | +8.00 亿元 | | 理想汽车-W(02015) | 13.94 亿元 | -3918.97 万元 | | 泡泡玛特(09992) | 13.49 亿元 | +8996.36 万元 | | 中芯国际(00981) | 12.78 亿元 | +2.48 亿元 | | 小米集团-W(01810) | 10.05 亿元 | -1.44 亿元 | | 比亚迪电子(00285) | 9.79 亿元 | +2.18 亿元 | | 康方生物(09926) | 7.28 亿元 | +1.38 亿元 | | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 腾讯控股(00700) | 45.54 亿元 | +7.18 ...

投资要点 腾讯控股今日涨1.70%，短线资金持续流入，前5日加仓416万股。 阿里巴巴-W今日涨0.60%，短线资金以流入为主，前5日加仓1654万股。 中芯国际今日涨3.14%，短线资金流入趋缓，前5日加仓784万股。 晶泰控股今日涨12.42%，短线资金加速流入，前5日加仓2319万股。 小米集团-W今日跌0.55%，短线资金以流入为主，前5日加仓6177万股。 泡泡玛特今日涨7.87%，短线资金延续流出趋势，前5日减持326万股。 注：由于港交所T+2结算，实际为向前递延两个交易日的前5日数据。 | | | 1322.93 智通财经8月6日讯（编辑 冯轶）据Wind数据显示，南向资金今日成交约1259.74亿港元，较前一日微幅下滑；约为今日恒指成交总额的58.53%，占比近两日 连续抬高。 全天恒指横盘震荡，南向资金净流入约94.85亿港元，其中沪港股通净流入约44.69亿港元，深港股通净流入约50.16亿港元。 个股方面，交易所数据显示，今日南向资金 大幅净买入：腾讯控股(0700.HK)15.18亿港元；阿里巴巴-W(09988.HK)8.76亿港元；中芯国际(00981.HK)6.12亿港元；晶泰 ...

8月6日消息，南向资金今日成交1259.74亿港元，净流入约94.85亿港元。其中沪港股通净流入约44.69亿 港元，深港股通净流入约50.16亿港元 交易所数据显示，8月6日南向资金动向： 大幅净买入：腾讯控股(00700.HK)15.18亿港元、阿里巴巴-W(09988.HK)8.76亿港元、中芯国际 (00981.HK)6.12亿港元、晶泰控股(02228.HK)5.33亿港元、康方生物(09926.HK)1.38亿港元、理想汽车- W(02015.HK)1.19亿港元。 晶泰控股今日涨12.42%，沪港股通净买入4.75亿港元，深港股通净买入5750.15万港元。 康方生物今日涨5.03%，深港股通净买入1.38亿港元。 理想汽车W今日跌5.35%，沪港股通净买入1.58亿港元，深港股通净卖出3918.97万港元。 小米集团W今日跌0.55%，沪港股通净卖出8501.64万港元，深港股通净卖出14410.94万港元。 泡泡玛特今日涨7.87%，沪港股通净卖出31306.92万港元，深港股通净买入8996.36万港元。 美团W今日跌1.46%，沪港股通净买入2.37亿港元，深港股通净卖出38412.99 ...

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound trading, with a total net buy of 94.85 billion HKD on August 6, 2023, indicating strong investor interest in certain stocks, particularly Tencent, Alibaba, and SMIC, while Xiaomi faced notable net selling [1][4]. Group 1: Northbound Trading Activity - Northbound trading through Stock Connect saw a net buy of 44.69 billion HKD from Shanghai and 50.16 billion HKD from Shenzhen [1]. - The most bought stocks included Tencent (00700), Alibaba-W (09988), and SMIC (00981) [1]. - Xiaomi Group-W (01810) was the most sold stock, with a net sell of 2.29 billion HKD [6]. Group 2: Individual Stock Performance - Tencent Holdings (00700) had a net buy of 26.36 billion HKD, with total trading volume of 45.54 billion HKD, reflecting a net inflow of 7.18 billion HKD [2]. - Alibaba-W (09988) saw a net buy of 19.21 billion HKD, with total trading volume of 31.64 billion HKD, resulting in a net inflow of 6.78 billion HKD [2]. - SMIC (00981) recorded a net buy of 13.47 billion HKD, with a total trading volume of 23.30 billion HKD, leading to a net inflow of 3.64 billion HKD [2]. Group 3: Company-Specific News - Tencent's new mobile game "无畏契约" is anticipated to generate annual revenue of 5 to 6 billion CNY, with over 50 million pre-registrations [4]. - Alibaba launched a new membership system integrating various services, marking a strategic shift towards a comprehensive consumer platform [5]. - SMIC is expected to report a quarterly revenue decline for the first time in two years, with a guidance range of 4% to 6% [5]. - Crystal Technology (02228) secured a record order of approximately 470 billion HKD (59.9 billion USD) for drug development collaboration [6].

Group 1 - The core viewpoint of the report is that Gallium Nitride (GaN) is the most promising power semiconductor in consumer electronics, electric vehicles, and renewable energy sectors, with Innoscience (02577) being the largest GaN IDM company globally [1] - The report highlights that Innoscience has a significant advantage as a Chinese company, given that China is the largest potential GaN market, producing approximately 55% of the world's smartphones, which will rapidly adopt GaN-based fast charging technology [1] - Innoscience plans to increase its production capacity sixfold by 2028, which is expected to significantly reduce costs and drive industry adoption [1] Group 2 - The report predicts that Innoscience will achieve a gross margin of 21% by the second half of 2025, nearing breakeven in 2026, and generating positive cash flow by 2027, with a projected net profit of 685 million RMB [1]

Core Viewpoint - The company, Hitec, is recognized for its GaN (Gallium Nitride) solutions, being the only Chinese chip enterprise selected by Nvidia, highlighting its leadership in GaN production and patent ownership [1] Group 1: Company Capabilities - Hitec has developed six major process technologies, including GaAs (Gallium Arsenide) passive and active chip processes, GaN power chip processes, GaN RF power amplifier chip processes, optoelectronic sensing chip processes, and SiC (Silicon Carbide) power chip processes [1] - The company's products are applicable in various fields such as 5G mobile communication, radar detection, new energy vehicles, consumer electronics, optical fiber communication, and 3D sensing [1]

Market Overview - On August 5, the Hang Seng Index rose by 0.68%, with total southbound trading amounting to HKD 129.701 billion, including buy transactions of HKD 76.563 billion and sell transactions of HKD 53.138 billion, resulting in a net buy of HKD 23.426 billion [1] Southbound Trading Details - The southbound trading through Stock Connect (Shenzhen) had a total trading amount of HKD 47.198 billion, with buy transactions of HKD 28.343 billion and sell transactions of HKD 18.854 billion, leading to a net buy of HKD 9.489 billion [1] - The southbound trading through Stock Connect (Shanghai) had a total trading amount of HKD 82.504 billion, with buy transactions of HKD 48.220 billion and sell transactions of HKD 34.284 billion, resulting in a net buy of HKD 13.936 billion [1] Active Stocks - The most actively traded stock by southbound funds was the Tracker Fund of Hong Kong, with a total trading amount of HKD 6.3006 billion and a net buy of HKD 6.2929 billion, closing with a price increase of 0.63% [1] - Tencent Holdings and SMIC followed, with trading amounts of HKD 4.898 billion and HKD 3.569 billion, respectively [1] - A total of 12 stocks experienced net buying, with Tencent Holdings seeing a net buy of HKD 0.832 billion and Southern Hang Seng Technology a net buy of HKD 0.798 billion [1] Continuous Net Buying - Among the stocks, Tencent Holdings, Xiaomi Group-W, and Kuaishou-W were continuously net bought for more than three days, with Tencent Holdings leading with a total net buy of HKD 4.426 billion over nine days [2] - Xiaomi Group-W followed closely with a net buy of HKD 4.411 billion over eight days, and Kuaishou-W with HKD 2.452 billion over four days [2] Summary of Active Stocks on August 5 - The following table summarizes the active stocks and their respective trading amounts, net buying, and daily price changes: | Code | Name | Trading Amount (HKD million) | Net Buy (HKD million) | Daily Change (%) | |--------|--------------------|------------------------------|-----------------------|-------------------| | 02800 | Tracker Fund | 6300.64 | 6292.99 | 0.63 | | 00700 | Tencent Holdings | 4897.79 | 831.72 | 1.64 | | 03033 | Southern Hang Seng Tech | 868.05 | 798.36 | 0.93 | | 01024 | Kuaishou-W | 2408.49 | 646.71 | 2.79 | | 02015 | Li Auto-W | 2927.53 | 586.03 | 1.58 | | 09988 | Alibaba-W | 3391.32 | 511.50 | -0.17 | | 01357 | Meituan | 2976.58 | 386.43 | -6.92 | | 09926 | CanSino Biologics | 877.47 | 290.20 | 7.17 | | 03690 | Meituan-W | 901.74 | 270.26 | -0.08 | | 01810 | Xiaomi Group-W | 2887.14 | 248.22 | -0.46 | | 02577 | InnoCare Pharma | 2303.82 | 232.89 | -6.65 | | 00981 | SMIC | 3568.78 | 121.27 | -0.97 | | 01788 | Guotai Junan International | 2225.67 | -5.07 | -0.94 | [2]

（文章来源：证券时报网） 证券时报·数据宝统计显示，8月5日港股通（包括沪市港股通及深市港股通）成交活跃股合计成交365.34 亿港元，净买入金额为111.66亿港元。 8月5日上榜的成交活跃股中，英诺赛科通过港股通渠道成交金额为23.04亿港元，净买入金额为2.33亿港 元，不仅如此，该股已连续3日出现成交净买入，累计净买入金额为9.60亿港元，其间股价上涨 59.43%。（数据宝） 英诺赛科获南向资金连续3天净买入，累计净买入金额为9.60亿港元，股价累计上涨59.43%。 ...

深港通（南向）十大活跃成交公司 | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 腾讯控股(00700) | 19.54 亿元 | +3.05 亿元 | | 小米集团-W(01810) | 13.14 亿元 | +244.56 万元 | | 中芯国际(00981) | 12.65 亿元 | +2.74 亿元 | | 理想汽车-W(02015) | 12.52 亿元 | +3.00 亿元 | | 阿里巴巴-W(09988) | 12.19 亿元 | +2.55 亿元 | | 美图公司(01357) | 11.05 亿元 | +2.67 亿元 | | 快手-W(01024) | 9.07 亿元 | +3.05 亿元 | | 美团-W(03690) | 9.02 亿元 | +2.70 亿元 | | 康方生物(09926) | 8.77 亿元 | +2.90 亿元 | | 南方恒生科技(03033) | 8.68 亿元 | +7.98 亿元 | 智通财经APP获悉，2025年8月5日当天，盈富基金(02800)、腾讯控股(00700)、英诺赛科(02577)位居沪 港通（南向） ...

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound trading, indicating a positive sentiment among investors towards certain stocks and sectors, particularly technology and ETFs [1][6]. Group 1: Northbound Trading Activity - Northbound trading recorded a net buy of HKD 234.26 billion, with HKD 139.36 billion from the Shanghai Stock Connect and HKD 94.89 billion from the Shenzhen Stock Connect [1]. - The most purchased stocks included the Tracker Fund of Hong Kong (盈富基金, 02800), Tencent (00700), and the Southern Hang Seng Technology ETF (南方恒生科技, 03033) [1][6]. - The stock with the highest net sell was Guotai Junan International (国泰君安国际, 01788), with a net outflow of HKD 50.72 million [1][9]. Group 2: Individual Stock Performance - The Tracker Fund of Hong Kong (02800) saw a net inflow of HKD 62.93 billion, while Tencent (00700) had a net inflow of HKD 5.26 billion [2]. - Other notable net inflows included InnoCare Pharma (英诺赛科, 02577) with HKD 2.33 billion, and Alibaba (阿里巴巴-W, 09988) with HKD 2.57 billion [2][8]. - Li Auto (理想汽车-W, 02015) received a net inflow of HKD 5.86 billion following an announcement of configuration adjustments for its i8 model [7]. Group 3: Sector Insights - The technology sector, which constitutes nearly one-third of the Hong Kong market, is expected to undergo a revaluation driven by improving fundamentals and policy expectations [6]. - Companies like Meitu (美图公司, 01357) reported a projected net profit increase of 65% to 72% year-on-year, indicating strong operational performance [7]. - UBS highlighted the potential of Akeso's core product AK112 in various cancer treatments, projecting significant revenue contributions from upcoming clinical trials [8].